newsfilter
← Latest News
GlobeNewswire·

Adaptimmune Reports Q3 Financial Results and Business Update

- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients - - Safety and response data from dose escalation...